AAAAAA
Results: 1-25/33
Authors:
CUNDY KC
SUEOKA C
LYNCH GR
GRIFFIN L
LEE WA
SHAW JP
Citation: Kc. Cundy et al., PHARMACOKINETICS AND BIOAVAILABILITY OF THE ANTI-HUMAN-IMMUNODEFICIENCY-VIRUS NUCLEOTIDE ANALOG 9-[(R)-2-(PHOSPHONOMETHOXY)PROPYL]ADENINE (PMPA) IN DOGS, Antimicrobial agents and chemotherapy, 42(3), 1998, pp. 687-690
Authors:
HORSFALL MWJ
SHAW JP
HIGHTON J
CRANCH PJ
Citation: Mwj. Horsfall et al., CHANGING PATTERNS IN THE USE OF SLOW-ACTING ANTIRHEUMATIC DRUGS FOR THE TREATMENT OF RHEUMATOID-ARTHRITIS, New Zealand medical journal, 111(1067), 1998, pp. 200-203
Authors:
ARIMILLI MN
KIM CU
DOUGHERTY J
MULATO A
OLIYAI R
SHAW JP
CUNDY KC
BISCHOFBERGER N
Citation: Mn. Arimilli et al., SYNTHESIS, IN-VITRO BIOLOGICAL EVALUATION AND ORAL BIOAVAILABILITY OF9-[2-(PHOSPHONOMETHOXY)PROPYL]ADENINE (PMPA) PRODRUGS, Antiviral chemistry & chemotherapy, 8(6), 1997, pp. 557-564
Authors:
SHAW JP
SUEOKA CM
OLIYAI R
LEE WA
ARIMILLI MN
KIM CU
CUNDY KC
Citation: Jp. Shaw et al., METABOLISM AND PHARMACOKINETICS OF NOVEL ORAL PRODRUGS OF 9-[(R)-2-(PHOSPHONOMETHOXY)PROPYL]ADENINE (PMPA) IN DOGS, Pharmaceutical research, 14(12), 1997, pp. 1824-1829
Authors:
SHAW JP
LOUIE MS
KRISHNAMURTHY VV
ARIMILLI MN
JONES RJ
BIDGOOD AM
LEE WA
CUNDY KC
Citation: Jp. Shaw et al., PHARMACOKINETICS AND METABOLISM OF SELECTED PRODRUGS OF PMEA IN RATS, Drug metabolism and disposition, 25(3), 1997, pp. 362-366
Authors:
CUNDY KC
SUE IL
VISOR GC
MARSHBURN J
NAKAMURA C
LEE WA
SHAW JP
Citation: Kc. Cundy et al., ORAL FORMULATIONS OF ADEFOVIR DIPIVOXIL - IN-VITRO DISSOLUTION AND IN-VIVO BIOAVAILABILITY IN DOGS, Journal of pharmaceutical sciences, 86(12), 1997, pp. 1334-1338
Authors:
SHAW JP
PETSKO GA
RINGE D
Citation: Jp. Shaw et al., DETERMINATION OF THE STRUCTURE OF ALANINE RACEMASE FROM BACILLUS-STEAROTHERMOPHILUS AT 1.9-ANGSTROM RESOLUTION, Biochemistry, 36(6), 1997, pp. 1329-1342
Authors:
FAWCETT JP
SHAW JP
COCKBURN M
BROOKE M
BARBEZAT GO
Citation: Jp. Fawcett et al., SEROPREVALENCE OF HELICOBACTER-PYLORI IN A BIRTH COHORT OF 21-YEAR-OLD NEW-ZEALANDERS, European journal of gastroenterology & hepatology, 8(4), 1996, pp. 365-369
Authors:
CUNDY KC
LYNCH G
SHAW JP
HITCHCOCK MJM
LEE WA
Citation: Kc. Cundy et al., DISTRIBUTION AND METABOLISM OF INTRAVITREAL CIDOFOVIR AND CYCLIC HPMPC IN RABBITS, Current eye research, 15(5), 1996, pp. 569-576
Authors:
LEE WA
LYNCH G
SHAW JP
HITCHCOCK MJ
CUNDY KC
Citation: Wa. Lee et al., DISTRIBUTION AND METABOLISM OF INTRAVITREAL CIDOFOVIR AND CYCLIC HPMPC IN RABBITS, Investigative ophthalmology & visual science, 37(3), 1996, pp. 2679-2679
Authors:
SHAW JP
TAN EW
BLACKMAN AG
Citation: Jp. Shaw et al., METHYL 2-BENZOYLOXY-3-OXO-3-PHENYLPROPANOATE, Acta crystallographica. Section C, Crystal structure communications, 52, 1996, pp. 2883-2885
Authors:
CUNDY KC
BIDGOOD AM
LYNCH G
SHAW JP
GRIFFIN L
LEE WA
Citation: Kc. Cundy et al., PHARMACOKINETICS, BIOAVAILABILITY, METABOLISM, AND TISSUE DISTRIBUTION OF CIDOFOVIR (HPMPC) AND CYCLIC HPMPC IN RATS, Drug metabolism and disposition, 24(7), 1996, pp. 745-752
Authors:
SHAW JP
TAN EW
Citation: Jp. Shaw et Ew. Tan, SELECTIVE BROMINATION OF ALPHA-CHLORO AND ALPHA-BROMO CARBOXYLIC-ACIDDERIVATIVES, Journal of organic chemistry, 61(16), 1996, pp. 5635-5637
Authors:
KAO AC
VANTRIGT P
SHAEFFERMCCALL GS
SHAW JP
KUZIL BB
PAGE RD
HIGGINBOTHAM MB
Citation: Ac. Kao et al., ALLOGRAFT DIASTOLIC DYSFUNCTION AND CHRONOTROPIC INCOMPETENCE LIMIT CARDIAC-OUTPUT RESPONSE TO EXERCISE 2 TO 6 YEARS AFTER HEART-TRANSPLANTATION, The Journal of heart and lung transplantation, 14(1), 1995, pp. 11-22
Authors:
SHAW JP
HARAYAMA S
Citation: Jp. Shaw et S. Harayama, CHARACTERIZATION IN-VITRO OF THE HYDROXYLASE COMPONENT OF XYLENE MONOOXYGENASE, THE FIRST ENZYME OF THE TOL-PLASMID-ENCODED PATHWAY FOR THEMINERALIZATION OF TOLUENE AND XYLENES, Journal of fermentation and bioengineering, 79(3), 1995, pp. 195-199
Authors:
HARAYAMA S
INOUE J
SHAW JP
REKIK M
Citation: S. Harayama et al., CHARACTERIZATION OF XYLENE MONOOXYGENASE, BENZYL ALCOHOL-DEHYDROGENASE AND BENZALDEHYDE DEHYDROGENASE ENCODED BY TOL PLASMID OF PSEUDOMONAS-PUTIDA, Journal of cellular biochemistry, 1995, pp. 39-39
Authors:
SHAW JP
FISHBACK JA
CUNDY KC
LEE WA
Citation: Jp. Shaw et al., A NOVEL OLIGODEOXYNUCLEOTIDE INHIBITOR OF THROMBIN .1. IN-VITRO METABOLIC STABILITY IN PLASMA AND SERUM, Pharmaceutical research, 12(12), 1995, pp. 1937-1942
Authors:
LEE WA
FISHBACK JA
SHAW JP
BOCK LC
GRIFFIN LC
CUNDY KC
Citation: Wa. Lee et al., A NOVEL OLIGODEOXYNUCLEOTIDE INHIBITOR OF THROMBIN .2. PHARMACOKINETICS IN THE CYNOMOLGUS MONKEY, Pharmaceutical research, 12(12), 1995, pp. 1943-1947
Authors:
TAGHAVI E
MENKES DB
HOWARD RC
MASON PA
SHAW JP
SPEARS GFS
Citation: E. Taghavi et al., PREMENSTRUAL-SYNDROME - A DOUBLE-BLIND CONTROLLED TRIAL OF DESIPRAMINE AND METHYLSCOPOLAMINE, International clinical psychopharmacology, 10(2), 1995, pp. 119-122
Authors:
SHAW JP
TAN EW
BLACKMAN AG
Citation: Jp. Shaw et al., HOMOCHIRAL METHYL )-2-BENZENESULFONYL-OXY-4-BROMO-4-METHYLPENTANOATE, Acta crystallographica. Section C, Crystal structure communications, 51, 1995, pp. 1411-1412
Authors:
SHAW JP
TAN EW
BLACKMAN AG
Citation: Jp. Shaw et al., HOMOCHIRAL METHYL (S)-2-BENZOYLOXY-4-BROMO-4-METHYLPENTANOATE, Acta crystallographica. Section C, Crystal structure communications, 51, 1995, pp. 2583-2584
Authors:
SHAW JP
ENG WT
BLACKMAN AG
Citation: Jp. Shaw et al., HOMOCHIRAL METHYL (2R,3S)-3-BROMO-2-CHLORO-3-PHENYLPROPANOATE, Acta crystallographica. Section C, Crystal structure communications, 51, 1995, pp. 134-135
Authors:
INOUE J
SHAW JP
REKIK M
HARAYAMA S
Citation: J. Inoue et al., OVERLAPPING SUBSTRATE SPECIFICITIES OF BENZALDEHYDE DEHYDROGENASE (THE XYLC GENE-PRODUCT) AND 2-HYDROXYMUCONIC SEMIALDEHYDE DEHYDROGENASE (THE XYLG GENE-PRODUCT) ENCODED BY TOL PLASMID PWWO OF PSEUDOMONAS-PUTIDA, Journal of bacteriology, 177(5), 1995, pp. 1196-1201
Authors:
KAUFMAN MH
CHANG HH
SHAW JP
Citation: Mh. Kaufman et al., CRANIOFACIAL ABNORMALITIES IN HOMOZYGOUS SMALL EYE (SEY SEY) EMBRYOS AND NEWBORN MICE/, Journal of Anatomy, 186, 1995, pp. 607-617
Authors:
PLATANIAS LC
RATAIN MJ
OBRIEN S
LARSON RA
VARDIMAN JW
SHAW JP
WILLIAMS SF
BARON JM
PARKER K
WOODWORTH TG
Citation: Lc. Platanias et al., PHASE-I TRIAL OF A GENETICALLY-ENGINEERED INTERLEUKIN-2 FUSION TOXIN (DAB(486)IL-2) AS A 6-HOUR INTRAVENOUS-INFUSION IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES, Leukemia & lymphoma, 14(3-4), 1994, pp. 257-262